23.05.2024 • NewsEuroAPIanimal health

EuroAPI Secures €130-150 Million Animal Health Contract

EuroAPI has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company.

As part of this collaboration, EuroAPI will supply its client with a key veterinary product. The total contract value is expected to range between €130 and 150 million, over the 2025-2029 period. 

“The conclusion of this major contract secures the long-term supply of a complex chemical molecule, crucial for veterinary use. This is a true recognition of EuroAPI’s know-how and of the reliability of the premium service we offer to our customers,” commented Ludwig de Mot, Chief Executive Officer of EuroAPI. “This agreement will be a key driver of our FOCUS-27 project sales trajectory.”

EuroAPI has expertise within the animal health sector with many customers and products in its portfolio such as hormones, prostaglandins and complex synthesis molecules. The value of the global animal health market has been estimated by Health for Animals at $41.8 billion (€38.6 billion) in 2023 and is expected to reach $56.8 billion (€52.5 billion) by 2030, at a CAGR of 4.5%.

© Adobe Stock
© Adobe Stock

Company

Logo:

EuroAPI

15 rue Traversière
75012 Paris
France

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read